Haematology News and Research RSS Feed - Haematology News and Research

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits. [More]
Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. [More]
One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in the UK are believed to be deficient in vitamin B12 – that’s an astonishing six million people suffering from the consequences of having less than the optimum amount of B12 in their system. [More]
CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union. [More]
Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016. [More]
Real-life data show feasibility of imatinib discontinuation in CML

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. [More]
Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients. [More]
New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib). [More]
Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia-lymphoma or peripheral T-cell lymphoma. [More]
Beckman Coulter Releases Compact DxH 500 Hematology System with CE Mark

Beckman Coulter Releases Compact DxH 500 Hematology System with CE Mark

Beckman Coulter Diagnostics has released the DxH 500 haematology system with CE Mark, an open-vial instrument offering a throughput of up to 60 samples per hour. [More]
New personalized DNA-based digital assay has potential to dramatically impact CML management

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued. [More]
Simple blood test could predict relapse in AML patients

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. [More]
Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan has today launched a new tissue typing method that could significantly improve stem cell transplant outcomes. [More]
Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Our skin is covered in millions of bacteria and most of them help keep us healthy. However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells. [More]
Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia. [More]
Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies. [More]
Three researchers recognised for their contributions to Australian medical research

Three researchers recognised for their contributions to Australian medical research

Three top Walter and Eliza Hall Institute researchers have been recognised for their contributions to Australian medical research, with their election as fellows of the Australian Academy of Health and Medical Sciences. [More]
New report sets out plans to improve cure rate, quality of life for childhood cancer survivors in Europe

New report sets out plans to improve cure rate, quality of life for childhood cancer survivors in Europe

Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major problems that need to be overcome, says a report from SIOPE, the European Society for Paediatric Oncology, launched at the 2015 European Cancer Congress today. [More]
Advertisement
Advertisement